Surgical monovision reasonable alternative for carefully screened presbyopes
November 11th 2006Surgical monovision is an attractive option for the patient with presbyopia who seeks refractive surgery and expects glasses- and contact lens-free vision after the procedure, said Mark J. Mannis, MD, at Refractive Surgery 2006.
Physicians discuss validity of monocular treatment trial for glaucoma medication
November 11th 2006Should physicians abandon the monocular treatment trial for assessing the efficacy of a glaucoma medication? That was the question debated in a point-counterpoint session during the glaucoma subspecialty day meeting.
LASIK may be OK for some autoimmune patients
November 10th 2006Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.
Short-term steroid use helps heal ocular surface before refractive surgery
November 10th 2006Short-term use of topical steroids used in conjunction with other long-term therapies can help heal the ocular surface in patients considering refractive surgery, said Deepinder K. Dhaliwal, MD, of the University of Pittsburgh School of Medicine.
Short-term follow-up of intravitreal bevacizumab indicates drug is safe in study
November 10th 2006Short-term results show that bevacizumab (Avastin, Genentech) seems to be safe and effective for neovascular age-related macular degeneration (AMD), reported Philip Rosenfeld, MD, PhD, during Retina Subspecialty Day.
MARINA 2-year study results show positive treatment effect of ranibizumab
November 10th 2006Ranibizumab (Lucentis, Genentech) for treatment of neovascular age-related macular degeneration (AMD) was shown to prevent moderate vision loss over 24 months and to result in improved vision in some patients in the MARINA Study, according to Joan Miller, MD, who reported the results during Retina Subspecialty Day.
LASIK may be OK for some autoimmune patients
November 10th 2006Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.
'No evidence' that refractive surgery causes chronic dry eye
November 10th 2006Although almost half of all patients who undergo LASIK report dry eye symptoms, there is no real evidence that the refractive procedure causes chronic dry eye, according to James P. McCulley, MD, FACS, UT Southwestern Medical Center, Fort Worth.
Long-term AREDS results show sustained treatment benefit for AMD
November 10th 2006The long-term results of the multicenter Age-Related Eye Disease Study (AREDS) indicated that the beneficial effect of treatment with antioxidants and zinc with copper persisted 10 years after the AREDS 1 trial ended, said Emily Chew, MD.
Signs of pellucid marginal degeneration should rule out refractive surgery
November 10th 2006Pellucid marginal degeneration is a subtle condition that could lead to corneal ectasia following laser eye surgery. Although it is atypical and rare, clinicians should learn how to identify pellucid and screen patients for it preoperatively, said Yaron S. Rabinowitz, MD, director of ophthalmology research, Cedars Sinai Medical Center, Los Angeles.
'Food Dude' to deliver ASCRS' Kraff lecture
November 6th 2006A world-renowned authority on the role of nutrition and lifestyle in the prevention of disease will deliver the Manus C. Kraff Lecture on Science and Medicine at the 2006 Symposium of the American Society of Cataract and Refractive Surgery in April.
National search focuses on vision advocates
November 6th 2006Prevent Blindness America (PBA), the nation's oldest and largest non-profit eye health and safety organization, is beginning its application process for the 2007 Eyes on Capitol Hill campaign. This event is designed to allow those affected by real-life vision issues an opportunity to discuss their experiences with their government representatives. The event will begin Feb. 28 in Washington, DC, with discussions on federal funding efforts for vision programs and research and seminars on how participants can become effective advocates in their own communities. The following day, participants will make office visits with congressional members.
Annual ASCRS survey of refractive trends show phakic IOLs gaining ground
November 1st 2006The annual American Society of Cata-ract and Refractive Surgery (ASCRS) survey on trends in refractive surgery was expanded this year to include other refractive surgery-related topics. Stephen Wexler, MD, provided the highlights of the survey at this year's annual meeting.
Aggressive dry eye treatment at all stages boosts patient satisfaction after LASIK
November 1st 2006Las Vegas-A rigorous preoperative dry eye treatment regimen can help ensure patient satisfaction after LASIK whether the IntraLase femtosecond laser (IntraLase Corp) or the Amadeus microkeratome (Advanced Medical Optics) was used to create the flap, according to Kent L. Wellish, MD.
Surgeon: intracorneal ring segments successfully treat keratoconus
November 1st 2006Los Angeles-Intracorneal ring segments (Intacs, Addition Technology Inc.) carry hope of success for patients with keratoconus, especially when the channels for the ring segments are created using the IntraLase femtosecond laser (IntraLase Corp.).
Keratoprosthesis yielding impressive outcomes
November 1st 2006Albany, NY-Multicenter data indicate that the Dohlman-Doane type I (Boston) keratoprosthesis is a viable option for visual rehabilitation in eyes in which multiple penetrating keratoplasties have failed or that have a poor prognosis for primary keratoplasty, said Mich?l W. Belin, MD.
Drugs, prophylaxis reduce the incidence of infection after cataract surgery
November 1st 2006Los Angeles-The rates of infection after cataract surgery can be reduced by a meticulous approach to controlling the microbes on the ocular surface and in the eye. The use of fourth-generation fluoroquinolones can better control the microorganisms that have grown resistant to previous generations of the drugs.